Acacia Pharma Raises £15M for Cancer Supportive Care
September 04, 2013
U.K.-based Acacia Pharma, a pharmaceutical company specializing in the development of drugs for cancer supportive care, has raised £15 million ($23.3 million) in Series B financing led by Fidelity Biosciences and Novo A/S. Proceeds will be used to advance clinical development of its products, as well as to develop commercial presentation. Dr. Alex Pasteur of Fidelity Biosciences and Dr. Martin Edwards of Novo A/S have joined the company's Board as non-executive directors.